|
Clenbuterol dilutes bronchial tubes viscous secretion and promotes its better secretion. It also has a tocolytic effect. It is used for prevention and reduction of bronchospasm at bronchial asthma and asthmatic bronchitis.
See two trials results:
In a double-blind cross-over trial of clenbuterol in bronchial asthma in 19 asthmatic patients with reversible airways obstruction, oral administration of both Clenbuterol (40 microgram) and Salbutamol (4 mg) caused significantly greater increased in peak expiratory flow rate (PEFR) than placebo. A trial also showed longer lasting of Clenbuterol. The patients' subjective assessment suggested the relief of their symptoms by the active drugs. Side-effects were minimal.
Another study was carried out in 6 patients with bronchial asthma to investigate the effects of Clenbuterol on peripheral airway obstruction. The basal lung functions of the patients were almost within normal range in both vital capacity (VC) and forced expiratory volume in 1 second (FEV1), but their maximal flow rates were lower in effort-independent phase of both maximal expiratory flow volume (MEFV) curve and partial expiratory flow volume (PEFV) curve. Furthermore, they demonstrated marked basal frequency dependence of dynamic compliance [CDdyn]. Oral administration of Clenbuterol (40 µg) produced a significant increase in the maximal flow in effort-independent phase of both MEFV and PEFV curves, and markedly decreased frequency dependence of CDdyn in comparison with the baseline values, while it improved both VC and FEV1 to a lesser extent. These results suggest that Clenbuterol preferentially reduced the peripheral airway obstruction in bronchial asthma.
|
